Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: Quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine

1. Grob, J.-J.
2. Amonkar, M.M.
3. Martin-Algarra, S.
4. Demidov, L.V.
5. Goodman, V.
6. Grotzinger, K.
7. Haney, P.
8. Kämpgen, E.
9. Karaszewska, B.
10. Mauch, C.
11. Miller, W.H.
12. Millward, M.
13. Mirakhur, B.
14. Rutkowski, P.
15. Chiarion-Sileni, V.
16. Swann, S.
17. Hauschild, A.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1093/ANNONC/MDU154 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus